Noticias de IONS_US

Mercado

Noticias del mercado

Últimas noticias sobre IONS_US — 420 novedades recientes. Análisis, balances, opiniones y cobertura de prensa.

Ticker: IONS_US ✕ 420 resultados
23/07/2026 IONS_US — PR Newswire
Ionis Pharmaceuticals, Inc. (IONS) Faces Investor Scrutiny After Surprise Trial Failure Drives Stock Down 23% - HBSS

/PRNewswire/ -- Los inversores de Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) vieron caer el precio de sus acciones 20,19 dólares (-23%) el 9 de julio de 2026 después del comercial...

23/07/2026 IONS_US — vinanet.vn
Ionis Pharmaceuticals (IONS) Surges 4.28% – Biotech Momentum Builds Above Key Support - Ease of Movement
23/07/2026 IONS_US — simplywall.st
US High Growth Tech Stocks to Watch for Potential Expansion
23/07/2026 IONS_US — TradingKey ES ← EN
IONS|Ionis Pharmaceuticals Inc|Precio:56.420|Variación%:+0.550

IONS|Ionis Pharmaceuticals Inc|Price:56.420|Chg%:+0.550

23/07/2026 IONS_US — PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ionis Pharmaceuticals, Inc. - IONS

/PRNewswire/ -- Pomerantz LLP está investigando reclamaciones en nombre de inversores de Ionis Pharmaceuticals, Inc. ("Ionis" o la "Compañía") (NASDAQ: IONS). Semejante...

22/07/2026 IONS_US — BioWorld News
Arrowhead rises on phase III hypertriglyceridemia readout
22/07/2026 IONS_US — Seeking Alpha
Arrowhead Pharmaceuticals: Redemplo Meets High Expectations In SHTG Trials (NASDAQ:ARWR)
22/07/2026 IONS_US — Yahoo Finance
Earnings Preview: Ionis Pharmaceuticals (IONS) Q2 Earnings Expected to Decline
22/07/2026 IONS_US — Seeking Alpha
Ionis drops as Arrowhead posts late-stage trial win for lipid-lowering drug
22/07/2026 IONS_US — MarketBeat
114,334 Shares in Ionis Pharmaceuticals, Inc. $IONS Purchased by SEB Asset Management AB
21/07/2026 IONS_US — ACCESS Newswire
Ionis Pharmaceuticals, Inc. (IONS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation
21/07/2026 IONS_US — GuruFocus
Ionis Pharmaceuticals, Inc. (IONS) Shows Oversold Potential with Low RSI
21/07/2026 IONS_US — MSN ES ← EN
¿Cómo se compara el nuevo medicamento contra el Alzheimer de Biogen con los medicamentos aprobados?

How does Biogen’s novel Alzheimer’s drug compare to approved drugs

21/07/2026 IONS_US — Intellectia AI
Ionis Pharmaceuticals Under Investigation for Securities Fraud
21/07/2026 IONS_US — GuruFocus ES ← EN
Ionis Pharmaceuticals, Inc. (IONS) muestra potencial de sobreventa con un RSI bajo

Ionis Pharmaceuticals, Inc. (IONS) Shows Oversold Potential with Low RSI

21/07/2026 IONS_US — Stockhouse
2026-07-21 | Ionis Pharmaceuticals, Inc. (IONS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | NDAQ:IONS | Press Release
21/07/2026 IONS_US — GuruFocus ES ← EN
Ionis Pharmaceuticals, Inc. (IONS) muestra potencial de sobreventa con un RSI bajo

Ionis Pharmaceuticals, Inc. (IONS) Shows Oversold Potential with Low RSI

21/07/2026 IONS_US — Trefis
Ionis Pharmaceuticals Stock Slides 39% Over 9 Straight Down Days

Una venta masiva persistente en un nombre de biotecnología exige una mirada más cercana a los fundamentos comerciales subyacentes. Las acciones de Ionis Pharmaceuticals (IONS) han bajado durante 9 días hábiles consecutivos, una pérdida acumulada del 38,7%. La caída ha borrado alrededor de 5 dólares.

20/07/2026 IONS_US — ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Ionis Pharmaceuticals, Inc. (IONS) And Encourages Investors to Connect
20/07/2026 IONS_US — The National Law Review
Bronstein, Gewirtz & Grossman, LLC Is Investigating Ionis Pharmac

Página 12 de 21